HN1抗体—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of HN1 expression in HeLa cell lysate.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:150 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:500 dilution.    

  
  

The HN1 antibody is a monoclonal antibody that targets hemagglutinin neuraminidase (HN), a surface glycoprotein found in certain paramyxoviruses, such as human parainfluenza viruses (HPIVs) and Newcastle disease virus (NDV). HN plays a critical role in viral entry by mediating both host cell receptor binding (hemagglutinin activity) and enzymatic cleavage of sialic acid residues (neuraminidase activity), facilitating viral release and spread.

First described in the context of NDV research, HN1 was developed to study HN's structural and functional properties, aiding in the understanding of viral pathogenesis and host immune responses. Its specificity for conserved epitopes on HN has made it a valuable tool in diagnostics, vaccine development, and antiviral research. For instance, HN1 has been used to block viral entry in vitro, highlighting its potential therapeutic utility.

Recent studies also explore HN1's application in oncolytic virotherapy, leveraging NDV's propensity to selectively replicate in cancer cells. By targeting HN, the antibody may enhance immune recognition of virus-infected tumor cells. Despite its promise, challenges remain in optimizing HN1's efficacy and safety for clinical use. Ongoing research focuses on engineering HN1-derived biologics, such as bispecific antibodies or antibody-drug conjugates, to improve targeting precision and therapeutic outcomes against both viral infections and cancers.